Fortune 45 LLC Boosts Stake in Eli Lilly and Company $LLY

Fortune 45 LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 15.2% during the second quarter, Holdings Channel reports. The fund owned 605 shares of the company’s stock after purchasing an additional 80 shares during the period. Eli Lilly and Company makes up about 0.3% of Fortune 45 LLC’s holdings, making the stock its 28th biggest holding. Fortune 45 LLC’s holdings in Eli Lilly and Company were worth $472,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $27,000. Blume Capital Management Inc. grew its stake in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares during the last quarter. IMG Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $35,000. Financial Gravity Asset Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $40,000. Finally, TD Capital Management LLC grew its stake in shares of Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. JPMorgan Chase & Co. lowered their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research report on Friday, October 10th. Finally, HSBC upped their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $938.61.

Eli Lilly and Company Stock Performance

LLY stock opened at $810.78 on Thursday. The stock has a market capitalization of $767.37 billion, a PE ratio of 52.99, a price-to-earnings-growth ratio of 1.22 and a beta of 0.47. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $935.63. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock’s 50 day simple moving average is $775.02 and its 200 day simple moving average is $770.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 39.22%.

Insider Activity

In other news, Director Jamere Jackson purchased 200 shares of the stock in a transaction dated Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders purchased 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.